Vertex Pharms Inc Drug Patent Portfolio
Vertex Pharms Inc owns 4 orange book drugs protected by 49 US patents Given below is the list of Vertex Pharms Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10793547 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | 08 Dec, 2037 | Active |
US11179367 | Pharmaceutical compositions for treating cystic fibrosis | 08 Dec, 2037 | Active |
US11453655 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | 08 Dec, 2037 | Active |
US11517564 | Methods of treatment for cystic fibrosis | 08 Dec, 2037 | Active |
US10758534 | NA | 06 Oct, 2035 | Active |
US11426407 | Modulators of cystic fibrosis transmembrane conductance regulator | 06 Oct, 2035 | Active |
US10206877 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 14 Apr, 2035 | Active |
US11951212 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 14 Apr, 2035 | Active |
US10058546 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof | 15 Jul, 2033 | Active |
US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof | 15 Jul, 2033 | Active |
US10272046 | Pharmaceutical composition and administrations thereof | 27 Feb, 2033 | Active |
US11147770 | Pharmaceutical composition and administrations thereof | 27 Feb, 2033 | Active |
US11752106 | Pharmaceutical composition and administrations thereof | 27 Feb, 2033 | Active |
US8883206 | Pharmaceutical composition and administrations thereof | 27 Feb, 2033 | Active |
US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | 25 Mar, 2031 | Active |
US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | 25 Mar, 2031 | Active |
US8993600 | Modulators of ATP-binding cassette transporters | 11 Dec, 2030 | Active |
US8507534 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | 20 Sep, 2030 | Active |
US8716338 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | 20 Sep, 2030 | Active |
US9192606 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | 29 Sep, 2029 | Active |
US10646481 | Pharmaceutical composition and administrations thereof | 13 Aug, 2029 | Active |
US11564916 | Pharmaceutical composition and administrations thereof | 13 Aug, 2029 | Active |
US8846718 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | 02 Jul, 2029 | Active |
US10076513 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | 04 Dec, 2028 | Active |
US10597384 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | 04 Dec, 2028 | Active |
US11052075 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | 04 Dec, 2028 | Active |
US12065432 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | 04 Dec, 2028 | Active |
US8653103 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | 04 Dec, 2028 | Active |
US9150552 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | 04 Dec, 2028 | Active |
US8415387 | Modulators of ATP-binding cassette transporters | 12 Nov, 2027 | Active |
US8324242 | Modulators of ATP-binding cassette transporters | 05 Aug, 2027 | Active |
US7776905 | Modulators of ATP-binding cassette transporters | 03 Jun, 2027 | Active |
US7495103 | Modulators of ATP-binding cassette transporters | 20 May, 2027 | Active |
US7645789 | Indole derivatives as CFTR modulators | 01 May, 2027 | Active |
US8598181 | Modulators of ATP-binding cassette transporters | 01 May, 2027 | Active |
US8623905 | Modulators of ATP-binding cassette transporters | 01 May, 2027 | Active |
US10022352 | Modulators of ATP-binding cassette transporters | 09 Apr, 2027 | Active |
US10239867 | Modulators of ATP-binding cassette transporters | 09 Apr, 2027 | Active |
US11639347 | Modulators of ATP-binding cassette transporters | 09 Apr, 2027 | Active |
US9974781 | Modulators of ATP-binding cassette transporters | 09 Apr, 2027 | Active |
US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
US7973038 | Modulators of ATP-binding cassette transporters | 08 Nov, 2026 | Active |
US8741933 | Modulators of ATP-binding cassette transporters | 08 Nov, 2026 | Active |
US9216969 | Modulators of ATP-binding cassette transporters | 08 Nov, 2026 | Active |
US8354427 | Modulators of ATP-binding cassette transporters | 06 Jul, 2026 | Active |
US8629162 | Modulators of ATP-binding cassette transporters | 24 Jun, 2025 | Active |
Latest Legal Activities on Vertex Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vertex Pharms Inc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jul, 2024 | US8354427 |
Payment of Maintenance Fee, 12th Year, Large Entity | 04 Jun, 2024 | US8324242 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 04 Jun, 2024 | US8324242 (Litigated) |
Email Notification
Critical
| 09 Apr, 2024 | US11951212 |
Recordation of Patent eGrant | 09 Apr, 2024 | US11951212 |
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951212 |
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951212 |
Patent eGrant Notification | 09 Apr, 2024 | US11951212 |
Mail Patent eGrant Notification | 09 Apr, 2024 | US11951212 |
Payment of Maintenance Fee, 4th Year, Large Entity | 08 Apr, 2024 | US10793547 |
Email Notification
Critical
| 21 Mar, 2024 | US11951212 |
Issue Notification Mailed
Critical
| 20 Mar, 2024 | US11951212 |
Application Is Considered Ready for Issue
Critical
| 05 Mar, 2024 | US11951212 |
Dispatch to FDC | 05 Mar, 2024 | US11951212 |
Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2024 | US10758534 |
Vertex Pharms Inc Drug Patents' Oppositions Filed in EPO
Vertex Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2017, by Alfred E. Tiefenbacher (Gmbh & Co. Kg). This opposition was filed on patent number EP11715637A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP17204189A | Sep, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
EP17204189A | Sep, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
EP17204189A | Sep, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP15849396A | May, 2021 | Generics [UK] Limited | Granted and Under Opposition |
EP10708442A | Oct, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP15721912A | Feb, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
EP06848237A | Nov, 2017 | Georg Kalhammer/Stephan Teipel | Opposition rejected |
EP11715637A | May, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Patent maintained as amended |
Vertex Pharms Inc's Family Patents
Vertex Pharms Inc Drug List
Given below is the complete list of Vertex Pharms Inc's drugs and the patents protecting them.
1. Kalydeco
Kalydeco is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10272046 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US11147770 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US11752106 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US8883206 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US10646481 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US11564916 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US8324242 | Modulators of ATP-binding cassette transporters |
05 Aug, 2027
(2 years from now)
| Active |
US7495103 | Modulators of ATP-binding cassette transporters |
20 May, 2027
(2 years from now)
| Active |
US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8354427 | Modulators of ATP-binding cassette transporters |
06 Jul, 2026
(1 year, 8 months from now)
| Active |
US8629162 | Modulators of ATP-binding cassette transporters |
24 Jun, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kalydeco's drug page
2. Orkambi
Orkambi is protected by 22 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8993600 | Modulators of ATP-binding cassette transporters |
11 Dec, 2030
(6 years from now)
| Active |
US8507534 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
20 Sep, 2030
(5 years from now)
| Active |
US8716338 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
20 Sep, 2030
(5 years from now)
| Active |
US9192606 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
29 Sep, 2029
(4 years from now)
| Active |
US10646481 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US11564916 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US8846718 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
02 Jul, 2029
(4 years from now)
| Active |
US10076513 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
04 Dec, 2028
(4 years from now)
| Active |
US10597384 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
04 Dec, 2028
(4 years from now)
| Active |
US11052075 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
04 Dec, 2028
(4 years from now)
| Active |
US12065432 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
04 Dec, 2028
(4 years from now)
| Active |
US8653103 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
04 Dec, 2028
(4 years from now)
| Active |
US9150552 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
04 Dec, 2028
(4 years from now)
| Active |
US8324242 | Modulators of ATP-binding cassette transporters |
05 Aug, 2027
(2 years from now)
| Active |
US7495103 | Modulators of ATP-binding cassette transporters |
20 May, 2027
(2 years from now)
| Active |
US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US7973038 | Modulators of ATP-binding cassette transporters |
08 Nov, 2026
(2 years from now)
| Active |
US8741933 | Modulators of ATP-binding cassette transporters |
08 Nov, 2026
(2 years from now)
| Active |
US9216969 | Modulators of ATP-binding cassette transporters |
08 Nov, 2026
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orkambi's drug page
3. Symdeko (copackaged)
Symdeko (copackaged) is protected by 25 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10206877 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
14 Apr, 2035
(10 years from now)
| Active |
US11951212 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
14 Apr, 2035
(10 years from now)
| Active |
US10058546 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
15 Jul, 2033
(8 years from now)
| Active |
US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
15 Jul, 2033
(8 years from now)
| Active |
US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
25 Mar, 2031
(6 years from now)
| Active |
US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
25 Mar, 2031
(6 years from now)
| Active |
US10646481 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US11564916 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US8415387 | Modulators of ATP-binding cassette transporters |
12 Nov, 2027
(3 years from now)
| Active |
US8324242 | Modulators of ATP-binding cassette transporters |
05 Aug, 2027
(2 years from now)
| Active |
US7776905 | Modulators of ATP-binding cassette transporters |
03 Jun, 2027
(2 years from now)
| Active |
US7495103 | Modulators of ATP-binding cassette transporters |
20 May, 2027
(2 years from now)
| Active |
US7645789 | Indole derivatives as CFTR modulators |
01 May, 2027
(2 years from now)
| Active |
US8598181 | Modulators of ATP-binding cassette transporters |
01 May, 2027
(2 years from now)
| Active |
US8623905 | Modulators of ATP-binding cassette transporters |
01 May, 2027
(2 years from now)
| Active |
US10022352 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US10239867 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US11639347 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US9974781 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8354427 | Modulators of ATP-binding cassette transporters |
06 Jul, 2026
(1 year, 8 months from now)
| Active |
US8629162 | Modulators of ATP-binding cassette transporters |
24 Jun, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symdeko (copackaged)'s drug page
4. Trikafta (copackaged)
Trikafta (copackaged) is protected by 32 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10793547 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
08 Dec, 2037
(13 years from now)
| Active |
US11179367 | Pharmaceutical compositions for treating cystic fibrosis |
08 Dec, 2037
(13 years from now)
| Active |
US11453655 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
08 Dec, 2037
(13 years from now)
| Active |
US11517564 | Methods of treatment for cystic fibrosis |
08 Dec, 2037
(13 years from now)
| Active |
US10758534 | NA |
06 Oct, 2035
(10 years from now)
| Active |
US11426407 | Modulators of cystic fibrosis transmembrane conductance regulator |
06 Oct, 2035
(10 years from now)
| Active |
US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
15 Jul, 2033
(8 years from now)
| Active |
US10272046 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US11147770 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US11752106 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US8883206 | Pharmaceutical composition and administrations thereof |
27 Feb, 2033
(8 years from now)
| Active |
US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
25 Mar, 2031
(6 years from now)
| Active |
US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
25 Mar, 2031
(6 years from now)
| Active |
US10646481 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US11564916 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
US8415387 | Modulators of ATP-binding cassette transporters |
12 Nov, 2027
(3 years from now)
| Active |
US8324242 | Modulators of ATP-binding cassette transporters |
05 Aug, 2027
(2 years from now)
| Active |
US7776905 | Modulators of ATP-binding cassette transporters |
03 Jun, 2027
(2 years from now)
| Active |
US7495103 | Modulators of ATP-binding cassette transporters |
20 May, 2027
(2 years from now)
| Active |
US7645789 | Indole derivatives as CFTR modulators |
01 May, 2027
(2 years from now)
| Active |
US8598181 | Modulators of ATP-binding cassette transporters |
01 May, 2027
(2 years from now)
| Active |
US8623905 | Modulators of ATP-binding cassette transporters |
01 May, 2027
(2 years from now)
| Active |
US10022352 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US10239867 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US11639347 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US9974781 | Modulators of ATP-binding cassette transporters |
09 Apr, 2027
(2 years from now)
| Active |
US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
US8354427 | Modulators of ATP-binding cassette transporters |
06 Jul, 2026
(1 year, 8 months from now)
| Active |
US8629162 | Modulators of ATP-binding cassette transporters |
24 Jun, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trikafta (copackaged)'s drug page